cyclic GMP


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

GMP

 
3′,5′-GMP (cyclic GMP) cyclic guanosine monophosphate.

guanosine

 [gwah´no-sēn]
a nucleoside, guanine riboside, one of the major constituents of RNA.
cyclic guanosine monophosphate a cyclic nucleotide, guanosine 3′,5′-cyclic monophosphate, an intracellular “second messenger” similar in action to cyclic adenosine monophosphate; the two cyclic nucleotides activate different protein kinases and usually produce opposite effects on cell function. Abbreviated 3′,5′-GMP, cGMP, and cyclic GMP.
guanosine monophosphate (GMP) a nucleotide important in metabolism and RNA synthesis.
guanosine triphosphate (GTP) a nucleotide required for RNA synthesis and involved in energy metabolism.

cyclic GMP

n. Abbr. cGMP
A cyclic nucleotide of guanosine that is produced inside cells in response to external stimuli, such as hormones, and triggers various biochemical pathways within the cell.

cyclic GMP (guanosine monophosphate)

a nucleotide that usually produces cell responses opposite to those of CYCLIC AMP. Analogous with cAMP, it is present in much lower concentrations.
References in periodicals archive ?
Mice treated with sildenafil showed browning of the white fat after just a few days of treatment, which is believed to be the result of high cyclic GMP levels.
The recent direct evidence that the internal messenger is cyclic GMP rather than calcium ions comes out of experiments with a powerful, relatively new technique called "patch clamping" (SN: 11/7/81, p.
SAANDs inhibit a novel pattern of over-expressed cyclic GMP phosphodiesterases found in cancerous and precancerous cells.
These compounds inhibit a cyclic GMP phosphodiesterase and induce apoptosis (programmed cell death), but do not produce the side effects normally associated with traditional chemotherapeutic agents.
The dietary supplement is designed to augment nitric oxide and is not designed to inhibit the breakdown of cyclic GMP.
It achieves this selectivity by inhibiting certain cyclic GMP phosphodiesterases that are expressed at high levels in the abnormal cells, thus freeing those damaged cells to die through normal cellular processes.
Patent and Trademark Office generally covering cyclic GMP phosphodiesterase 2 and 5 inhibition to treat inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease.
Research has previously shown that these drugs act by inhibiting certain cellular proteins called cyclic GMP phosphodiesterases (cGMP PDEs) that are overexpressed in a variety of tumor types.
It achieves this selective activity by inhibiting certain cyclic GMP phosphodiesterases that are expressed at high levels in the abnormal cells, thus freeing those damaged cells to die through normal cellular processes.
CP461 and Cell Pathways' other selective apoptotic antineoplastic drugs (SAANDs) inhibit cyclic GMP (cGMP) phosphodiesterases 2 and 5, resulting in the activation of protein kinase G and the triggering of downstream cellular pathways leading to apoptosis (programmed cell death).

Full browser ?